LU91911I2 - Abiratérone et ses sels d'addition acide et ses 3 esters, en particulier l'acétate d'abiratérone - Google Patents

Abiratérone et ses sels d'addition acide et ses 3 esters, en particulier l'acétate d'abiratérone

Info

Publication number: LU91911I2
Authority: LU; Luxembourg
Prior art keywords: carbon atoms; beta; hydrogen atom; abiraterone; pyridyl
Prior art date: 1992-03-31

Application number

LU91911C

Other languages

English (en)

Original Assignee

Btg Int Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-31

Filing date

2011-12-07

Publication date

2012-02-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91911(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-03-31 Priority claimed from GB929207057A external-priority patent/GB9207057D0/en

1992-11-27 Priority claimed from GB929224880A external-priority patent/GB9224880D0/en

2011-12-07 Application filed by Btg Int Ltd filed Critical Btg Int Ltd

2012-02-07 Publication of LU91911I2 publication Critical patent/LU91911I2/fr

Links

239000002253 acid Substances 0.000 title abstract 2
150000003839 salts Chemical class 0.000 title abstract 2
229960000853 abiraterone Drugs 0.000 title 1
GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 title 1
229960004103 abiraterone acetate Drugs 0.000 title 1
UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 title 1
150000002148 esters Chemical class 0.000 title 1
125000004432 carbon atom Chemical group C* 0.000 abstract 6
125000000217 alkyl group Chemical group 0.000 abstract 5
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
230000001419 dependent effect Effects 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
239000003098 androgen Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
125000004043 oxo group Chemical group O=* 0.000 abstract 1
150000003431 steroids Chemical class 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LU91911C 1992-03-31 2011-12-07 Abiratérone et ses sels d'addition acide et ses 3 esters, en particulier l'acétate d'abiratérone LU91911I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB929207057A GB9207057D0 (en)	1992-03-31	1992-03-31	Steroids
GB929224880A GB9224880D0 (en)	1992-11-27	1992-11-27	Steroids
PCT/GB1993/000531 WO1993020097A1 (fr)	1992-03-31	1993-03-15	Steroïdes substitues-17 utiles pour le traitement du cancer

Publications (1)

Publication Number	Publication Date
LU91911I2 true LU91911I2 (fr)	2012-02-07

Family

ID=26300621

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91911C LU91911I2 (fr)	1992-03-31	2011-12-07	Abiratérone et ses sels d'addition acide et ses 3 esters, en particulier l'acétate d'abiratérone

Country Status (16)

Country	Link
EP (1)	EP0633893B1 (fr)
JP (1)	JP2742331B2 (fr)
KR (1)	KR100235135B1 (fr)
AT (1)	ATE186913T1 (fr)
AU (1)	AU668144B2 (fr)
CA (1)	CA2132449C (fr)
CZ (1)	CZ287434B6 (fr)
DE (2)	DE69327096T2 (fr)
DK (1)	DK0633893T3 (fr)
ES (1)	ES2138618T3 (fr)
GB (1)	GB2265624B (fr)
IL (1)	IL105078A (fr)
LU (1)	LU91911I2 (fr)
MX (1)	MX9301525A (fr)
NZ (1)	NZ249911A (fr)
WO (1)	WO1993020097A1 (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2127413T3 (es) *	1993-09-30	1999-04-16	Btg Int Ltd	Sintesis de esteroides 17-(3-piridilo).
HUT73855A (en) *	1993-10-27	1996-09-30	Merrell Pharma Inc	Delta16 unsaturated c17 heterocyclic steroids useful as steroid c17-20 lyase inhibitors, pharmaceutical compositions containing them and process for their production
CA2429133C (fr)	2000-11-17	2009-08-18	Takeda Chemical Industries, Ltd.	Nouveaux derives imidazole, procede de production correspondant et utilisation de ces derives
DE60144246D1 (de)	2000-11-20	2011-04-28	Takeda Pharmaceutical	Imidazolderivate, verfahren zu deren herstellung und deren verwendung
WO2002046186A1 (fr)	2000-12-08	2002-06-13	Takeda Chemical Industries, Ltd.	Dérivés thiazole substitués porteurs de groupes 3-pyridyl, procédé d'élaboration et leur utilisation
EP1463505A2 (fr) *	2001-12-13	2004-10-06	Abbott Laboratories	Derives de la 3-(phenyl-alkoxy)-5-(phenyl)-pyridine et composes similaires avec activite inhibiteur de kinase pour le traitement du cancer.
US8569275B2 (en)	2002-08-28	2013-10-29	Harbor Therapeutics, Inc.	Steroids having 7-oxgen and 17-heteroaryl substitution
WO2004019953A1 (fr) *	2002-08-28	2004-03-11	Hollis-Eden Pharmaceuticals, Inc.	Procedes de traitement therapeutique
GB0418900D0 (en)	2004-08-24	2004-09-29	Btg Int Ltd	Novel salt forms
EP1781683B1 (fr)	2004-08-24	2011-11-16	BTG International Limited	Procede de preparation de 17-vinyltriflates comme intermediaires
DE102006008074B4 (de) *	2006-02-22	2013-08-14	RUHR-UNIVERSITäT BOCHUM	Behandlung von Krebs mit Geruchsrezeptor-Liganden
HRP20130961T1 (hr)	2006-08-25	2013-11-22	Janssen Oncology, Inc.	Kombinacije za tretman raka
CA2838089A1 (fr) *	2006-08-25	2008-02-28	Cougar Biotechnology, Inc.	Procedes servant a traiter un cancer consistant a administrer un compose de la vitamine d et un agent therapeutique supplementaire et compositions les contenant
US20080051380A1 (en)	2006-08-25	2008-02-28	Auerbach Alan H	Methods and compositions for treating cancer
US20090124587A1 (en) *	2007-07-12	2009-05-14	Auerbach Alan H	METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
US20100048524A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP2393827B1 (fr) *	2009-02-05	2015-10-07	Tokai Pharmaceuticals, Inc.	Nouveaux promédicaments à base d'inhibiteurs cyp17 stéroïdiens/anti-androgènes
PE20121048A1 (es)	2009-06-26	2012-08-25	Novartis Ag	Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
AU2010319697B2 (en) *	2009-11-13	2016-05-19	Tokai Pharmaceuticals, Inc.	Mammalian metabolites of steroids
WO2011088160A2 (fr) *	2010-01-15	2011-07-21	Biomarin Pharmaceutical Inc.	Nouveaux inhibiteurs de cyp17
KR101594660B1 (ko)	2010-08-04	2016-02-16	펠피큐어 파마슈티걸즈 아이엔씨	전립선 암종의 치료를 위한 병용 요법
EP2627648A1 (fr)	2010-09-16	2013-08-21	Novartis AG	INHIBITEURS DE LA 17a-HYDROXYLASE/C17,20-LYASE
CN102558274B (zh) *	2010-12-08	2014-10-15	深圳万乐药业有限公司	一种适合工业化生产醋酸阿比特龙的合成方法
BR112013017635A2 (pt) *	2010-12-16	2016-10-11	Biomarin Pharm Inc	inibidores de cyp11b, cyp17 e/ou cyp21
CN102558275A (zh) *	2010-12-20	2012-07-11	天津药物研究院	α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
MX359399B (es)	2011-04-28	2018-09-27	Novartis Ag	Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
CN102321142A (zh) *	2011-09-29	2012-01-18	重庆医药工业研究院有限责任公司	一种醋酸阿比特龙晶型及其制备方法
DE102011083725A1 (de) *	2011-09-29	2013-04-04	Bayer Pharma AG	Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN104066744B (zh)	2011-10-10	2017-03-22	扎克系统公司	用于制备17‑取代的甾体的方法
CN103059090B (zh) *	2011-10-20	2016-06-22	连云港润众制药有限公司	醋酸阿比特龙草酸盐以及醋酸阿比特龙的纯化方法
MX367640B (es)	2011-11-30	2019-08-29	Astrazeneca Ab	Tratamiento combinado del cáncer.
CN103172690B (zh) *	2011-12-23	2016-08-24	重庆医药工业研究院有限责任公司	醋酸阿比特龙及其中间体的制备方法
EP2607371A1 (fr)	2011-12-23	2013-06-26	Crystal Pharma, S.A.U.	Procédés de préparation d'abiratérone et composés associés
CN103193849B (zh) *	2012-01-04	2016-05-04	连云港润众制药有限公司	一种高纯度醋酸阿比特龙的制备方法
CN103254265B (zh)	2012-02-21	2016-07-13	上海希迈医药科技有限公司	醋酸阿比特龙三氟乙酸盐及其制备方法和应用
CN102627681B (zh) *	2012-03-23	2016-04-13	山东新时代药业有限公司	一种醋酸阿比特龙的制备方法
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
WO2013159225A1 (fr) *	2012-04-23	2013-10-31	Alphora Research Inc.	Procédé de préparation de stéroïdes 17-substitués
CA2872541A1 (fr)	2012-06-06	2013-12-12	Novartis Ag	Combinaison d'un inhibiteur de 17-alpha-hydroxylase (c17,20-lyase) et d'un inhibiteur specifique de pi-3k pour le traitement d'une maladie tumorale
CN102731605B (zh) *	2012-06-19	2016-04-13	鲁南制药集团股份有限公司	一种醋酸阿比特龙的纯化方法
AU2013289344A1 (en) *	2012-07-10	2015-02-05	Bayer Pharma Aktiengesellschaft	3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
WO2014009434A1 (fr)	2012-07-11	2014-01-16	Sandoz Ag	Système d'administration de médicament auto-microémulsifiant à base d'abiratérone ou d'acétate d'abiratérone
WO2014009437A1 (fr)	2012-07-11	2014-01-16	Sandoz Ag	Stabilité d'oxydation d'acétate d'abiratérone
WO2014009436A1 (fr)	2012-07-11	2014-01-16	Sandoz Ag	Nanosuspension d'acétate d'abiratérone
WO2014016830A1 (fr) *	2012-07-25	2014-01-30	Mapi Pharma Ltd.	Procédé et intermédiaires utilisés pour la préparation de l'acétate d'abiratérone
WO2014058785A1 (fr)	2012-10-10	2014-04-17	Novartis Ag	Polythérapie
ITMI20121788A1 (it)	2012-10-22	2014-04-23	Olon Spa	Procedimento per la purificazione di abiraterone acetato
EP2917226A1 (fr)	2012-11-09	2015-09-16	Synthon BV	Processus de fabrication de l'intermédiaire 17-triflate d'abiratérone-3-acétate
WO2014071984A1 (fr)	2012-11-09	2014-05-15	Synthon Bv	Procédé de fabrication de 3-acétate d'abiratérone
TWI570131B (zh) *	2012-11-13	2017-02-11	賽克系統公司	製備１７－經取代類固醇之方法
WO2014075978A1 (fr)	2012-11-16	2014-05-22	Synthon B.V.	Procédé de production d'abiratérone-3-acétate impliquant une réaction de triflation énolique en présence d'un composé de type alcoxy-pyridine
CN103059091B (zh) *	2012-11-22	2017-04-19	常州靶点医药科技有限公司	一种避免重金属残留的醋酸阿比特龙的制备方法
CN103864878A (zh) *	2012-12-12	2014-06-18	天津大学	阿比特龙醋酸酯的制备方法
WO2014102833A2 (fr)	2012-12-31	2014-07-03	Hetero Research Foundation	Procédé de préparation d'acétate d'abiratérone
CA2904170A1 (fr)	2013-03-14	2014-09-25	University Of Maryland, Baltimore	Agents de diminution du recepteur des androgenes et leurs utilisations
AU2014241816B9 (en)	2013-03-14	2019-02-14	Pellficure Pharmaceuticals Inc.	Novel therapy for prostate carcinoma
PL2792682T3 (pl)	2013-04-19	2017-04-28	Zach System	Sposób wytwarzania stałej postaci octanu abirateronu
US20160176915A1 (en) *	2013-06-24	2016-06-23	Sun Pharmaceutical Industries Limited	Process for preparation of abiraterone acetate
US9650410B2 (en)	2013-07-29	2017-05-16	Industriale Chimica S.R.L.	Process for the preparation of abiraterone and abiraterone acetate
CA2919484C (fr)	2013-07-29	2021-05-11	Industriale Chimica S.R.L.	Procede de preparation d'abiraterone ou d'acetate d'abiraterone
ITMI20131861A1 (it) *	2013-11-08	2015-05-09	Ind Chimica Srl	Processo per la preparazione di abiraterone e abiraterone acetato
KR20160058774A (ko)	2013-08-12	2016-05-25	토카이 파마슈티컬, 아이엔씨.	안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
CN104558091B (zh) *	2013-10-16	2017-07-28	天津金耀集团有限公司	一种醋酸阿比特龙的合成方法
US9556219B2 (en)	2014-01-28	2017-01-31	Olon S.P.A.	Procedure for the preparation of abiraterone acetate and intermediates thereof
CN103965282B (zh)	2014-04-21	2016-01-20	武汉百科药物开发有限公司	一种醋酸阿比特龙的制备方法
US9315541B2 (en)	2014-05-20	2016-04-19	Olon S.P.A.	Process for the preparation of unsaturated trifluoromethanesulfonate steroid derivatives
EP3160450A1 (fr)	2014-06-30	2017-05-03	Galenicum Health S.L.	Compositions pharmaceutiques stables sous forme de comprimés à libération immédiate
CZ2014475A3 (cs)	2014-07-09	2016-01-20	Zentiva, K.S.	Způsob přípravy Abirateron acetátu o vysoké čistotě aplikovatelný v průmyslovém měřítku
WO2016040896A1 (fr)	2014-09-12	2016-03-17	Pellficure Pharmaceuticals, Inc.	Compositions et méthodes de traitement d'un carcinome de la prostate
CN114886852A (zh)	2014-12-05	2022-08-12	阿拉贡药品公司	抗癌组合物
RS62421B1 (sr)	2014-12-05	2021-10-29	Aragon Pharmaceuticals Inc	Anti-kancerogeni sastavi
EP3824908A1 (fr)	2015-04-10	2021-05-26	Capsugel Belgium NV	Formulations lipidiques d'acétate d'abiratérone
JP6842474B2 (ja) *	2016-02-02	2021-03-17	深▲セン▼市塔吉瑞生物医▲薬▼有限公司ＳｈｅｎｚｈｅｎＴａｒｇｅｔＲｘ，Ｉｎｃ．	ステロイド系化合物、当該化合物を含む組成物及びその使用
EA201892828A1 (ru)	2016-06-03	2019-05-31	Арагон Фармасьютикалз, Инк.	Противораковые композиции
WO2018023017A1 (fr)	2016-07-29	2018-02-01	Janssen Pharmaceutica Nv	Méthodes de traitement du cancer de la prostate
WO2018080933A1 (fr)	2016-10-24	2018-05-03	Pellficure Pharmaceuticals Inc.	Compositions pharmaceutiques de 5-hydroxy-2-méthylnaphtalène-1, 4-dione
US11865215B2 (en)	2018-04-26	2024-01-09	Synthon B.V.	Tablet compositions comprising abiraterone acetate
HU231297B1 (hu)	2018-07-31	2022-09-28	Richter Gedeon Nyrt	Stabil gyógyszerkészítmények és eljárás az előállításukra
CN110272465A (zh) *	2019-07-15	2019-09-24	成都贝诺科成生物科技有限公司	阿比特龙衍生物、其制备方法与应用
KR20220047589A (ko)	2019-08-08	2022-04-18	래크나 리미티드	암 치료 방법
EP3854384A1 (fr)	2020-01-27	2021-07-28	Adamed Pharma S.A.	Formulation pharmaceutique comprenant de l'acétate d'abiratérone
JP2023524794A (ja)	2020-05-08	2023-06-13	ヤンセンファーマシューティカエヌ．ベー．	アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置
EP3944860A1 (fr)	2020-07-30	2022-02-02	Galenicum Health S.L.U.	Abiratérone pour utilisation dans un procédé de traitement du cancer
JP2025506402A (ja)	2022-02-04	2025-03-11	ヤンセンファーマシューティカエヌ．ベー．	転移性去勢抵抗性前立腺癌及びｈｒｒ変化を有する患者における臨床アウトカムを改善するためのニラパリブ及び酢酸アビラテロン＋プレドニゾン
CN116917306A (zh) *	2022-02-18	2023-10-20	上海醇健医药技术有限公司	17-吡啶基-10α-甲基-甾体衍生物及中间体化合物、其制备方法、其用途、以及其药物组合物
CN116589519A (zh) *	2023-05-17	2023-08-15	江西川奇药业有限公司	一种醋酸阿比特龙及其中间产物的合成方法
WO2025027138A1 (fr)	2023-08-02	2025-02-06	Janssen Pharmaceutica Nv	Combinaison de niraparib et d'abiratérone destinée à être utilisée dans le traitement du cancer de la prostate résistant à la castration métastatique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA882717B (en) *	1987-04-22	1988-10-17	Merrell Dow Pharmaceuticals Inc.	17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors
US4966898A (en) *	1989-08-15	1990-10-30	Merrell Dow Pharmaceuticals Inc.	4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors

1993
- 1993-03-15 ES ES93906670T patent/ES2138618T3/es not_active Expired - Lifetime
- 1993-03-15 AT AT93906670T patent/ATE186913T1/de active
- 1993-03-15 WO PCT/GB1993/000531 patent/WO1993020097A1/fr not_active Ceased
- 1993-03-15 DE DE69327096T patent/DE69327096T2/de not_active Expired - Lifetime
- 1993-03-15 DK DK93906670T patent/DK0633893T3/da active
- 1993-03-15 EP EP93906670A patent/EP0633893B1/fr not_active Expired - Lifetime
- 1993-03-15 CZ CZ19942337A patent/CZ287434B6/cs not_active IP Right Cessation
- 1993-03-15 CA CA002132449A patent/CA2132449C/fr not_active Expired - Lifetime
- 1993-03-15 NZ NZ249911A patent/NZ249911A/en not_active IP Right Cessation
- 1993-03-15 AU AU37584/93A patent/AU668144B2/en not_active Expired
- 1993-03-15 JP JP5517187A patent/JP2742331B2/ja not_active Expired - Lifetime
- 1993-03-15 KR KR1019940703426A patent/KR100235135B1/ko not_active Expired - Lifetime
- 1993-03-15 GB GB9305269A patent/GB2265624B/en not_active Expired - Lifetime
- 1993-03-16 IL IL105078A patent/IL105078A/xx active Protection Beyond IP Right Term
- 1993-03-18 MX MX9301525A patent/MX9301525A/es active IP Right Grant
2011
- 2011-12-07 LU LU91911C patent/LU91911I2/fr unknown
2012
- 2012-01-12 DE DE201212000012 patent/DE122012000012I1/de active Pending

Also Published As

Publication number	Publication date
EP0633893A1 (fr)	1995-01-18
MX9301525A (es)	1994-02-28
GB2265624B (en)	1995-04-19
KR100235135B1 (ko)	2000-01-15
CA2132449A1 (fr)	1993-10-14
DK0633893T3 (da)	2000-04-17
GB9305269D0 (en)	1993-05-05
IL105078A0 (en)	1993-07-08
DE69327096D1 (de)	1999-12-30
NZ249911A (en)	1996-06-25
CZ287434B6 (en)	2000-11-15
DE122012000012I1 (de)	2012-06-14
ES2138618T3 (es)	2000-01-16
IL105078A (en)	1997-11-20
DE69327096T2 (de)	2000-06-21
GB2265624A (en)	1993-10-06
AU668144B2 (en)	1996-04-26
ATE186913T1 (de)	1999-12-15
JPH07505377A (ja)	1995-06-15
EP0633893B1 (fr)	1999-11-24
AU3758493A (en)	1993-11-08
CZ233794A3 (en)	1995-02-15
CA2132449C (fr)	2002-09-10
JP2742331B2 (ja)	1998-04-22
WO1993020097A1 (fr)	1993-10-14
KR950700923A (ko)	1995-02-20

Publication	Publication Date	Title
KR950700923A (ko)	1995-02-20	암치료에 유용한 17-치환된 스테로이드(17-substituted steroids useful in cancer treatment)
RU2210574C2 (ru)	2003-08-20	Очищенные стероидсульфаматные соединения, эстрон-сульфаматы
ZA899671B (en)	1990-11-28	Phosphinic acid substituted steroids as inhibitors of steroid 5-alpha-reductase
TW240215B (fr)	1995-02-11
NO20004998L (no)	2000-12-06	Fettsyrederivater av gallesyrer og gallesyrederivater
PT873351E (pt)	2001-01-31	Novos derivados ester nitrito/nitrato de esteroides uteis como drogas anti-inflamatorias
IL72702A0 (en)	1984-11-30	Steroidal carboxylic acid esters,their manufacture and pharmaceutical compositions containing them
RU97104003A (ru)	1999-05-10	Производные эстра-1,3,5(10)-триена, способ их получения и содержащие их фармацевтические композиции
PT92168B (pt)	1995-07-03	Processo para a preparacao de composicoes farmaceuticas contendo derivados de nucleos de estrogenios para provocar a inibicao da actividade de esteroides sexuais
JP2000509388A (ja)	2000-07-25	抗炎症薬剤として有用なステロイドナイトレートエステル誘導体を含有する新規医薬組成物
PT88648A (pt)	1988-10-01	Process for the preparation of new androstane 17-carboxylic acid esters and a pharmaceutical composition containing same
ZA899670B (en)	1990-11-28	Phosphonic acid substituted steroids as steroid 5-alpha-reductase inhibitors
OA06613A (fr)	1981-08-31	Nouveaux dérivés d'amino-14 stéroïdes et procédé pour leur préparation.
US4780460A (en)	1988-10-25	Glycoesters of estradiol and estriol
ES8701749A1 (es)	1986-12-01	Un procedimiento para preparar nuevos derivados del 1,3-benzo-xatiol.
HUT45546A (en)	1988-07-28	Process for producing 6-alpha,9-alpha-difluoro-11-beta,17-alpha-dihydroxy-16-alpha-methyl-4-pregnene-3,20-dion derivatives
ES2260294T3 (es)	2006-11-01	17-metilen-esteroides halogenados en posicion 4, procedimientos para su preparacion y composiciones que contienen estos compuestos.
WO1990015067A3 (fr)	1991-01-24	NOUVEAUX PROCEDES D'OBTENTION DE 6-METHYL 19-NOR STEROIDES ET LEUR CONVERSION EN 19-NOR PREGNADIENES 17α-SUBSTITUES
DE3882956D1 (de)	1993-09-09	Gegen die zerebrale insuffizienz wirksame verbindungen.
TW343976B (en)	1998-11-01	17-substituted steroids useful in cancer treatment
GR22382B (el)	1961-10-21	Βελτιωσεις εις η σχετικως προς μεθοδους παρασκευης νεων στεροειδων ενωσεων.
GB961101A (en)	1964-06-17	Steroid compounds
ATE184016T1 (de)	1999-09-15	Verfahren zur herstellung von 16 alpha, 17 alpha- ketal steroid-derivaten